CN1304021C - 一种药物组合物及其制备方法 - Google Patents
一种药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1304021C CN1304021C CNB2005100119100A CN200510011910A CN1304021C CN 1304021 C CN1304021 C CN 1304021C CN B2005100119100 A CNB2005100119100 A CN B2005100119100A CN 200510011910 A CN200510011910 A CN 200510011910A CN 1304021 C CN1304021 C CN 1304021C
- Authority
- CN
- China
- Prior art keywords
- cimetidine
- ulcer
- stomach
- group
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 title abstract description 19
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims abstract description 95
- 229960001380 cimetidine Drugs 0.000 claims abstract description 78
- 239000003814 drug Substances 0.000 claims abstract description 68
- 208000025865 Ulcer Diseases 0.000 claims abstract description 45
- 231100000397 ulcer Toxicity 0.000 claims abstract description 45
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000002671 adjuvant Substances 0.000 claims abstract description 8
- 210000002784 stomach Anatomy 0.000 claims description 60
- 208000015181 infectious disease Diseases 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 28
- 239000002775 capsule Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 10
- 230000002183 duodenal effect Effects 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 22
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract description 21
- 229960000905 indomethacin Drugs 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000008439 repair process Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 description 53
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 28
- 238000012360 testing method Methods 0.000 description 18
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 10
- 235000011054 acetic acid Nutrition 0.000 description 10
- 238000003304 gavage Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 208000008469 Peptic Ulcer Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 208000000718 duodenal ulcer Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000004211 gastric acid Anatomy 0.000 description 7
- 210000001156 gastric mucosa Anatomy 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 208000011906 peptic ulcer disease Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 208000007107 Stomach Ulcer Diseases 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 201000005917 gastric ulcer Diseases 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 239000009517 FM 100 Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008925 spontaneous activity Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- -1 liquorice flavonoids compound Chemical class 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- IDWXQRMUCRXFAK-UHFFFAOYSA-N (2-phenyldiazenylhydrazinyl)benzene Chemical compound C=1C=CC=CC=1N=NNNC1=CC=CC=C1 IDWXQRMUCRXFAK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
- FOQYDURHXZVLFT-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylethanethioamide Chemical compound C=1C=CC=NC=1C(C(=S)N)C1=CC=CC=C1 FOQYDURHXZVLFT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 102000052874 Gastrin receptors Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960001498 benactyzine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical group CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
药物 | 动物数(只) | 剂量mg/kg | 溃疡面积(mm2) | 抑制率% | P值 |
对照组 | 10 | 72±42 | |||
复方西咪替丁组 | 101010 | 125250500 | 24±818±510±4 | 66.6775.0086.11 | <0.01<0.01<0.01 |
药物 | 动物数(只) | 剂量mg/kg | 溃疡面积(mm2) | 溃疡指数 | 抑制率% | P值 |
对照组 | 10 | 150±61 | 527±238 | |||
复方西咪替丁组 | 101010 | 125250500 | 132±4158±2049±25 | 358±200148±8198±88 | 32.0771.9281.40 | <0.05<0.01<0.01 |
药物 | 动物数(只) | 剂量mg/kg | 溃疡面积(mm2) | 抑制率% | P值 |
对照组 | 10 | 26.2±19.6 | |||
复方西咪替丁组 | 101010 | 125250500 | 10.4±7.92.9±1.90.8±0.7 | 66.3188.9396.95 | <0.01<0.01<0.01 |
组别 | 动物数(只) | 剂量mg/kg/日 | 溃疡面积(mm2)X±SD | 与对照组比较 | 与安胃疡组比较 | ||
抑制率% | P值 | 抑制率% | P值 | ||||
对照组 | 10 | 23.61±2.94 | |||||
安胃疡组 | 10 | 50 | 20.01±6.09 | 15.25 | >0.05 | ||
10 | 100 | 16.05±3.51 | 32.02 | <0.01 | |||
10 | 200 | 11.91±2.52 | 49.56 | <0.01 | |||
复方西咪替丁组 | 10 | 50 | 16.35±2.91 | 30.75 | <0.01 | 19.14 | >0.05 |
10 | 100 | 10.35±1.92 | 56.16 | <0.01 | 35.51 | <0.05 | |
10 | 200 | 6.12±3.12 | 74.08 | <0.01 | 48.61 | <0.01 |
药物 | 动物数(只) | 剂量mg/kg | 游离酸mEq/100mlX±SD | P值 | 总酸mEq/100mlX±SD | P值 |
对照组 | 10 | 6.36±1.58 | 9.43±0.72 | |||
复方西咪替丁组 | 10 | 125 | 4.44±1.46 | <0.05 | 7.97±1.37 | <0.01 |
10 | 500 | 3.70±1.90 | <0.01 | 7.40±1.30 | <0.01 |
组别 | 剂量(mg/kg) | 活动次数 | P值 |
对照组 | 540±108 | ||
复方西咪替丁组 | 250 | 548±125 | >0.05 |
复方西咪替丁组 | 500 | 534±145 | >0.05 |
剂量 | 血压(Kpa) | |||
(mg/kg) | 给药前 | 1小时 | 3小时 | 8小时 |
100 | 20.0±1.9 | 20.1±2.0 | 20.0±2.0 | 19.8±2.1 |
500 | 21.3±1.8 | 21.3±1.9 | 22.0±2.1 | 21.3±2.0 |
项目 | 剂量 | 时间 | |||
(mg/kg) | 给药前 | 1小时 | 3小时 | 8小时 | |
心率 | 100 | 149±16 | 150±17 | 150±18 | 148±18 |
500 | 150±16 | 149±18 | 147±16 | 145±16 | |
P-R(ms) | 100 | 88±8 | 89±9 | 88±9 | 89±8 |
500 | 86±7 | 85±7 | 86±8 | 87±9 | |
QRS(ms) | 100 | 50±5 | 50±5 | 51±5 | 52±4 |
500 | 48±5 | 48±5 | 49±6 | 50±5 | |
Q-T(ms) | 100 | 250±24 | 251±24 | 252±26 | 254±27 |
500 | 260±27 | 261±25 | 263±27 | 265±28 |
项目 | 剂量 | 时间 | |||
(mg/kg) | 给药前 | 1小时 | 3小时 | 8小时 | |
频率(次/分) | 100 | 32±2 | 32±2 | 33±2 | 33±3 |
500 | 30±2 | 29±2 | 30±2 | 29±2 | |
幅度(mm) | 100 | 8.6±1.0 | 8.5±1.1 | 8.6±1.1 | 8.4±1.2 |
500 | 8.0±0.9 | 8.1±1.0 | 8.1±1.1 | 8.0±1.1 |
组别 | 药物 | 剂量mg/kg | 动物数(只) | 溃疡面积(mm2)X±SD | 抑制率% | 比较(p值) | ||
与对照组 | 与1组 | 与2组 | ||||||
对照组 | 0.5%CMC | 10 | 69±41 | |||||
1组 | 安胃疡 | 400100 | 1010 | 40±2160±25 | 42.0313.04 | <0.05>0.05 | ||
2组 | 西咪替丁 | 10025 | 1010 | 48±2570±27 | 30.430.00 | >0.05>0.05 | >0.05>0.05 | |
3组 | 复方西咪替丁 | 500125 | 1010 | 8±625±10 | 88.4163.77 | <0.01<0.01 | <0.01<0.01 | <0.01<0.01 |
组别 | 药物 | 剂量mg/kg | 动物数(只) | 溃疡面积(mm2)X±SD | 抑制率% | 比较(p值) | ||
与对照组 | 与1组 | 与2组 | ||||||
对照组 | 0.5%CMC | 10 | 69±41 | |||||
1组 | 安胃疡 | 125250500 | 101010 | 65±1642±2636±12 | 5.8039.1347.83 | >0.05>0.05<0.05 | ||
2组 | 西咪替丁 | 125250500 | 101010 | 36±1226±1318±12 | 47.8362.3273.91 | <0.01<0.01<0.01 | <0.01>0.05>0.05 | |
3组 | 复方西咪替丁 | 125250500 | 101010 | 25±1019±98±6 | 63.7772.4688.41 | <0.01<0.01<0.01 | <0.01<0.05<0.05 | >0.05<0.05<0.05 |
试验值(腹腔) | ||
LD50 | 95%可信限 | |
日本产FM100 | 760mg/kg | 670-870mg/kg |
安胃疡 | 820mg/kg | 760-1010mg/kg |
复方西咪替丁 | 980mg/kg | 850-1120mg/kg |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100119100A CN1304021C (zh) | 2005-06-09 | 2005-06-09 | 一种药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100119100A CN1304021C (zh) | 2005-06-09 | 2005-06-09 | 一种药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1709310A CN1709310A (zh) | 2005-12-21 |
CN1304021C true CN1304021C (zh) | 2007-03-14 |
Family
ID=35705642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100119100A Active CN1304021C (zh) | 2005-06-09 | 2005-06-09 | 一种药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1304021C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110946838A (zh) * | 2019-12-18 | 2020-04-03 | 惠州市九惠制药股份有限公司 | 一种直接用于压片的复合辅料及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091010A (zh) * | 1993-02-20 | 1994-08-24 | 王尤理 | 一种胃药组合物——国光胃药 |
-
2005
- 2005-06-09 CN CNB2005100119100A patent/CN1304021C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091010A (zh) * | 1993-02-20 | 1994-08-24 | 王尤理 | 一种胃药组合物——国光胃药 |
Also Published As
Publication number | Publication date |
---|---|
CN1709310A (zh) | 2005-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1215833C (zh) | 快速崩解的甲基纤维素片剂 | |
CN1772011A (zh) | 银杏叶提取物组合物及其制备方法 | |
CN1631247A (zh) | 一种耐缺氧抗疲劳的保健食品及其制备工艺 | |
CN100339127C (zh) | 止咳、镇咳和润喉草药制剂的研制 | |
CN1304039C (zh) | 一种具有降压、降脂、定眩、定风作用的中药组合物及其制备方法和其用途 | |
CN1947757A (zh) | 地黄叶提取物及其制备方法和用途、用该提取物制备的药物 | |
CN1943675A (zh) | 清热化痰、止咳平喘的藏药药物组合物及其制备方法 | |
CN1895535A (zh) | 用于治疗咽喉疾病的中药制剂及其生产方法 | |
CN1304021C (zh) | 一种药物组合物及其制备方法 | |
CN1813819A (zh) | 猴头子实体或猴头菌丝体及培养物提取物及制剂和制法 | |
CN1723964A (zh) | 一种治疗咳喘、慢性支气管炎的药物 | |
CN1857362A (zh) | 金感康药物制剂及其制备方法 | |
CN1628662A (zh) | 具有镇痛作用的药物 | |
CN1190191C (zh) | 黄芩甙元在制备治前列腺疾病药物中的应用及其药物组合物 | |
CN1772026A (zh) | 一种返魂草提取物,它的提取方法及制剂 | |
CN101028518A (zh) | 含有硝酸酯类药物和伊伐布雷定的药物组合物 | |
CN1166402C (zh) | 一种具有保健作用的中药组合物 | |
CN100337665C (zh) | 治疗糖尿病的口服药物 | |
CN1283300C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN1323681C (zh) | 一种治疗上呼吸道感染的复方制剂及其在制药中的应用 | |
CN1723988A (zh) | 葛花苷的药物组合物及其应用 | |
CN1520818A (zh) | 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物 | |
CN1500487A (zh) | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 | |
CN1569021A (zh) | 一种阿奇霉素肠溶制剂及其制备方法 | |
CN1099285C (zh) | 新的镇痉剂和消炎药的组合物及其制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUIZHOU JIUHUI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUIZHOU JIUHUI PHARMACEUTICAL FACTORY Effective date: 20070216 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070216 Address after: 516007 Nan'an Road, Guangdong, Huizhou Patentee after: Huizhou-Jiuhui Pharmaceutical Co., Ltd. Address before: 516007 Nan'an Road, Guangdong, Huizhou Patentee before: Huizhou Jiuhui Pharmaceutical Factory |
|
C56 | Change in the name or address of the patentee |
Owner name: HUIZHOU JIUHUI PHARMACY CO., LTD. Free format text: FORMER NAME OR ADDRESS: HUIZHOU JIUHUI PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Nan'an Road, Huizhou, Guangdong Patentee after: Huizhou nine Hui pharmaceutical Limited by Share Ltd Address before: Nan'an Road, Huizhou, Guangdong Patentee before: Huizhou-Jiuhui Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: HUIZHOU CITY JIUHUI PHARMACY CO.,LTD. Free format text: FORMER NAME OR ADDRESS: HUIZHOU JIUHUI PHARMACEUTICAL CO., LTD. |
|
CI01 | Correction of invention patent gazette |
Correction item: Alteration of the patent holder Correct: delete False: Wrong announcement Number: 38 Page: 1555 Volume: 24 |
|
CP01 | Change in the name or title of a patent holder |
Address after: Nan'an Road, Huizhou, Guangdong Patentee after: Huizhou Jiuhui Pharmaceutical Co., Ltd. Address before: Nan'an Road, Huizhou, Guangdong Patentee before: Huizhou-Jiuhui Pharmaceutical Co., Ltd. |
|
ERR | Gazette correction |
Free format text: CORRECT: CHANGE OF PATENTEE; FROM: WRONG PUBLICATION TO: DELETION |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210818 Address after: 516000 office building of Henan an Dalang Du Jiuhui Pharmaceutical Co., Ltd., Huizhou City, Guangdong Province Patentee after: Huizhou Jiuhui Pharmaceutical Co.,Ltd. Address before: 516007 Nan'an Road, Guangdong, Huizhou Patentee before: JIUHUI PHARMACEUTICAL Co.,Ltd. |